LID-1 and NDO-LID ELISA
Enzyme immunoassay for IgG directed against the LID-1 fusion protein of ML0405 and ML2331. The IgG response is distinct from the IgM anti-PGL-I response and has been evaluated for treatment monitoring and pre-clinical case detection.
- Technology
- Serology (Antibody) · ELISA
- What it measures
- IgG against LID-1 fusion protein (ML0405-ML2331)
- Developer
- IDRI, now AAHI (Seattle, WA, USA)
- Specimen
- Venous blood
- Development status
- LDT with clinical validation
- Regulatory status
- None / RUO
- Intended use
- Treatment monitoring and pre-clinical case detection in contacts
- Main limitation
- Less sensitive in paucibacillary disease and available only in laboratories.
- Linked publications
- 34
- Collaborating institutions
- Fiocruz (Brazil), Federal University of Goiás (Goiânia, Brazil)
- TPP-1, confirming leprosy
- 33.5 of 100, low alignment
- TPP-2, infection in contacts
- 25.5 of 100, low alignment
Open this test in the landscapeAll 37 tests · Home